Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2017-2021
PRRS causes reproductive failure in breeding stock such as abortions and giving birth to stillborn, dyspnea in young pigs and sepsis. Mortality of sows and piglets of acute onset is above 40% while mortality of chronic onset is very low.
- Geography Covered
- Publication Date
Porcine reproductive and respiratory syndrome (PRRS) is an epidemic disease caused by porcine reproductive and respiratory syndrome virus (PRRSV). PRRS causes reproductive failure in breeding stock such as abortions and giving birth to stillborn, dyspnea in young pigs and sepsis. Mortality of sows and piglets of acute onset is above 40% while mortality of chronic onset is very low. Symptoms of chronic onset include respiratory tract illness and decrease of immune function and reproduction ability. At present, PRRS attacks in China's large-scale pig farms are mainly chronic PRRS.
According to CRI, animal vaccines are mainly classified into nation-planned compulsory immunity vaccines and non-compulsory immunity vaccines (commercial vaccines) in China. Most of the compulsory vaccines are purchased by the government at a lower price, which are distributed to pig farmers for free and are of poor quality. Partial large-scale farms have high requirements for animal vaccines, so they generally purchase high-quality vaccines from animal vaccine enterprises directly. Generally speaking, prices of PRRS vaccines for government procurement are only 10% that of commercial vaccines.
According to CRI, China is the largest pork producer and consumer in the world, accounting for nearly half of the global total output volume of pork. In 2016, output volume of pork was about 53 million tons in China, and the sales volume of hogs was about 685 million heads. In 2007, Ministry of Agriculture of China issued Technical Standards of Prevention and Treatment of Highly-pathogenic PRRS, including highly-pathogenic PRRS vaccines into national compulsory immunization plan. In 2016, Ministry of Agriculture of China claimed that compulsory immunization of highly-pathogenic PRRS was not to be implemented temporarily. In 2017, national compulsory immunization plan of PRRS was abandoned officially in National Compulsory Immunization Plan of Animal Epidemic Diseases, 2017.
According to CRI, China's PRRS Vaccine market is fiercely competitive in terms of the competition pattern. By June, 2017, there are about 30 PRRS vaccine producers, among which there are about 10 public companies. Major domestic manufacturing enterprises include Shanghai Hile Bio-pharmaceutical Co., Ltd., China Animal Husbandry Industry Co., Ltd., Qilu Animal Health Products Co., Ltd. and Harbin Weike Biotechnology Co., Ltd. in China's PRRS vaccine market. Boehringer Ingelheim Group is the major foreign-funded enterprise.
According to CRI, the market size declined by over 30% in 2016 compared to that in 2015 as the Chinese government no longer purchases PRRS vaccines since 2016. From the short run (within 3 years),exit of government procurement will cause declining sales volume of vaccines and shrinking market size to China's PRRS vaccine market. High price of commercial vaccines is the major cause. It is likely that small-scale farmers (with annual sales volume of no more than 200 heads) will not immunize pigs after PRRS vaccines are not included in government compulsory immunization plan in order to save the cost. Small-scale pig farmers still account for a large proportion of the total pig farmers at present.
It is estimated that the market size of PRRS vaccines will shrink in short term after the abandon of compulsory immunization (within 3 years). However, from the long run, small-scale farmers will gradually withdraw from market and the proportion of large-scale farms with annual sales volume of over 5,000 heads is growing as the cost of hog breeding keeps growing in China. These large-scale pig farms are the major driving forces in China's PRRS vaccine market as 95% of them will purchase commercial PRRS vaccines.
According to CRI, demand for pork will keep growing with the development of China's economy and the improvement of livelihood of Chinese residents, promoting the development of hog breeding industry. It is estimated that market size of PRRS vaccines will be smaller during 2017-2018 due to the termination of government procurement. However, with the rapid growth of the commercial PRRS vaccine market in China, the market size will increase again in 2019.
Readers can acquire the following information or more through this report:
-Incidence Status of Porcine Reproductive and Respiratory Syndrome
-Overview of China Hog Breeding Industry
-Policy Environment and Historical Government Procurement of PRRS Vaccines in China
-Supply and Demand Status of PRRS Vaccines in China
-Major Manufacturing Enterprises of PRRS Vaccines and their Operation Status in China
-Competition Status of PRRS Vaccine Market in China
-Market Opportunities and Driving Forces of PRRS Vaccine Market in China
-Threats and Challenges Confronted by PRRS Vaccine Market in China, 2017-2021
-Prospect of PRRS Vaccine Industry in China
Table of Contents
1 Status of PRRS Vaccine Market in China
1.1 Relevant Concepts of PRRS
1.1.1 Introduction to PRRS
1.1.2 Incidence Status of PRRS in China
1.2 Relevant Concepts of PRRS Vaccines
1.2.1 Definition of PRRS Vaccine
1.2.2 Classification of PRRS Vaccine
1.3 Research Methods of the Report
1.3.1 Parameters and Assumptions
1.3.2 Data Sources
1.3.3 About CRI
2 Factors Influencing Development of PRRS Vaccines in China, 2015-2017
2.1 Policies in China Animal Vaccine Industry
2.1.1 Analysis on Legislation of Animal Epidemic Prevention in China
2.1.2 Competent Authorities of Animal Epidemic Prevention in China
2.1.3 Appropriation Budget of Animal Epidemic Prevention in China
2.1.4 Scope of Animal Compulsory Immunization
2.1.5 Changes of Highly-pathogenic PRRS Immunization Policies
2.2 Overview on Hog Breeding in China, 2012-2016
2.2.1 Livestock Volume of Hogs
2.2.2 Fattened Volume of Hogs
2.2.3 Output Volume of Pork in China, 2012-2016
3 Operation Status of PRRS Vaccine Industry in China, 2012-2017
3.1 Supply of PRRS Vaccines in China's Market
3.1.1 Overview of PRRS Vaccine Producers
3.1.2 Production Capacity and Volume of PRRS Vaccines in China's Market
3.2 Demand for PRRS Vaccines in China's Market, 2012-2016
3.2.1 Overall Demand in PRRS Vaccine Market in China
3.2.2 PRRS Vaccines Procured by Government
3.2.3 Commercial PRRS Vaccines
3.3 Barriers to Entry of PRRS Vaccine Market in China
3.3.1 Policy Barriers
3.3.2 Technological Barriers
3.3.3 Sales Channel Barriers
3.4 Competition Structure of PRRS Vaccine Market in China
3.4.1 Bargaining Ability of Upstream Suppliers
3.4.2 Bargaining Ability of Downstream Clients
3.4.3 Internal Competition of the Industry
3.4.4 Potential Entrants
4 Major PRRS Vaccine Producers in China's Market, 2015-2017
4.1 Shanghai Hile Bio-pharmaceutical Co., Ltd.
4.1.1 Enterprise Profile
4.1.2 Operation Status of PRRS Vaccines
4.2 China Animal Husbandry Industry Co., Ltd.
4.2.1 Enterprise Profile
4.2.2 Operation Status of PRRS Vaccines
4.3 Qilu Animal Health Products Co., Ltd.
4.4 Boehringer Ingelheim Group, China
4.5 Harbin Weike Biotechnology Co., Ltd.
4.6 Pu-Like Bio-Enginerring Co., Ltd.
4.7 Tianbang Food Co., Ltd.
4.8 Beijing Dabeinong Technology Group Co., Ltd.
4.9 Tianjin Ringpu Bio-technology Co., Ltd.
4.10 Guangdong Winsun Pharmaceutical Co., Ltd.
4.11 Wuhan Chopper Biology Co., Ltd.
4.12 Guangdong Wens Food Group Co., Ltd.
4.13 Qingdao Yebio Bioengineering Co., Ltd.
4.14 Xinjiang Tecon Animal Husbandry Bio-Technology Co., Ltd.
5 Cost and Price Trends of PRRS Vaccines in China, 2015-2017
5.1 Production Cost Trend
5.1.1 Raw Material Price Trend
5.1.2 Labor Cost Trend
5.2 Price Trend of PRRS Vaccines in China's Market
5.2.1 Price Trend of PRRS Vaccines for Government Procurement
5.2.2 Price Trend of Commercial PRRS Vaccines
6 Prospect of PRRS Vaccine Industry in China, 2017-2021
6.1 Factors Influencing Development of PRRS Vaccine Industry in China, 2017-2021
6.1.1 Market Opportunities and Driving Forces of PRRS Vaccine Market
6.1.2 Threats and Challenges Confronted by PRRS Vaccine Industry
6.2 Forecast on Supply of PRRS Vaccines in China, 2017-2021
6.2.1 Forecast on Production Capacity of PRRS Vaccines
6.2.2 Forecast on Production Volume of PRRS Vaccines
6.3 Forecast on Demand in PRRS Vaccine Market in China, 2017-2021
6.3.1 Forecast on Market Size
6.3.2 Forecast on Market Trend
Chart Classification of PRRS Vaccines
Chart Major PRRS Vaccine Manufacturing Enterprises and Types in China's Market
Chart Market Price of PRRS Vaccines
Chart PRRS Epidemic Situation in China, 2015-2017
Chart Expenditure of the Chinese Government on Animal Epidemic Prevention, 2005-2017
Chart Sales Volume of Hogs in China, 2006-2016
Chart Output Volume of Pork in China, 2006-2016
Chart Major Types of PRRS Vaccines in China
Chart PRRS Vaccine Market Size in China, 2012- 2016
Chart Forecast on Output Volume of PRRS Vaccines in China, 2017-2021
Chart Sales Revenue of PRRS Vaccines of Shanghai Hile Bio-pharmaceutical Co., Ltd., 2012-2016
Chart Forecast on PRRS Vaccine Market Size in China, 2017-2021